US5882652A - Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids - Google Patents

Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids Download PDF

Info

Publication number
US5882652A
US5882652A US08/317,785 US31778594A US5882652A US 5882652 A US5882652 A US 5882652A US 31778594 A US31778594 A US 31778594A US 5882652 A US5882652 A US 5882652A
Authority
US
United States
Prior art keywords
cpv
capsids
recombinant
protein
empty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/317,785
Other languages
English (en)
Inventor
Elena Cortes Valdes
Carmen Vela Olmo
Jose Ignacio Casal Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inmunologia y Genetica Aplicada SA
Original Assignee
Inmunologia y Genetica Aplicada SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmunologia y Genetica Aplicada SA filed Critical Inmunologia y Genetica Aplicada SA
Priority to US08/317,785 priority Critical patent/US5882652A/en
Application granted granted Critical
Publication of US5882652A publication Critical patent/US5882652A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks

Definitions

  • the present invention relates in general to viral proteins and to assays and vaccines using the same and, in particular, to a protein related to the major antigen (VP2) of the Canine Parvovirus (CPV) capsid.
  • VP2 major antigen
  • CPV Canine Parvovirus
  • Such protein was produced in an expression vector of baculoviruses multiplied in a cell culture of a permissive host.
  • the protein obtained with the instant invention is singularly characterized in forming empty VP2 capsids that are useful in vaccine formulation.
  • the Canine Parvovirus belongs to the autonomous parvoviruses, causing severe enteritis in dogs of all ages and myocarditis in puppies less than 12 weeks old. CPV was first isolated in 1978 (Burtonboy, G. et al., Arch. Virol. 61:1-11, 1979; Appel et al., Vet. Rec. 105. 156-179, 1979). It is believed to have arisen as a natural variant of the feline panleukopenia virus (FPLV) or the mink enteritis virus (MEV). CPV infection is controlled using conventional vaccines based on live or inactivated viruses. However, since dogs are vaccinated before pregnancy, maternal antibodies can block attenuated live vaccine replication. Autonomous parvoviruses provide a good vector for recombinant subunit vaccine production for several reasons, inter alia:
  • the capsid proteins are structurally simple (no glycosylation, phosphorylation or acetylation is required).
  • the CPV capsid contains two proteins with broadly overlapping amino acid sequences, VP1 (82-84 KDa) and VP2 (67.70 KDa) (Paradiso et al. J. Gen. Virol. 39, 800-807, 1982.
  • Surleraux et al., Arch. Virol. 82, 233-240, 1984 ).
  • the parvovirus capsid has a diameter of 22 nm and holds some 10 VP1 copies and some 60 VP2 copies (Wobble et al., Biochemistry 23, 6565-6569, 1984), arranged as either homo- or heterodimers (Paradiso, J. Virol., 46, 94-102, 1983) though the precise capsid structure is unknown.
  • VP2 in full capsids (holding DNA) is preferentially broken down by proteolytic digestion into 63-67 KDa VP3 (Paradiso et al., Gen. Virol. 39, 800-807, 1982. Surleaux et al. Arch. Virol., 82, 233.240, 1984) after capsid assembly (Paradiso, J. Virol., 39, 800-807, 1981).
  • the said patent application relates to the expression of such products in E. coli bacterial vectors.
  • ACMNPV Autographa californica nuclear polyhedrosis virus
  • This added capacity of the VP2 protein obtained with our invention is further convenient in that other viral protein epitopes can be introduced in the said capsids by genetic manipulation of the recombinant baculoviruses, or by chemical manipulation of the actual capsids.
  • the present invention puts forth a new process for producing a recombinant subunit vaccine to protect dogs from CPV, cats from FPLV and minks from MEV.
  • the new vaccine produced thus can contain:
  • VP2 the CPV VP2 protein produced in an expression vector of baculoviruses multiplied in a cell culture of a permissive host (this protein hereinafter optionally referred to as "VP2 hereof"); or
  • the VP2 protein hereof is singularly characterized in forming empty VP2 capsids, optionally incorporating other viral protein epitopes by genetic manipulation of the recombinant baculoviruses or chemical manipulation of the actual capsids.
  • the object of the invention is therefore a new process for obtaining new improved subunit vaccines capable of protecting dogs, cats and minks respectively from CPV, FPLV and MEV infections.
  • the said vaccines can either contain the VP2 protein hereof or empty VP2 capsids formed by the said VP2 protein hereof, inasmuch as the said empty capsids have an enhanced hemagglutination activity and are highly immunogenic, excelling other recombinant proteins of these viruses produced heretofore in any other vector.
  • the new vaccines the invention provides and being one of their objects can contain either the said empty capsids with an immunologically acceptable diluent, with or without an adjuvant, or the VP2 protein hereof together with a diluent and an adjuvant.
  • the said empty VP2 capsids can be chemically or genetically manipulated to introduce other unrelated viral protein or peptide epitopes therein, the use of the said capsids both for CPV, FPLV and MEV vaccinal purposes and modified to incorporate other epitopes, thereby to provide a polyvalent vaccine, are further additional objects of this invention.
  • the VP2 protein obtained with the invention and the empty VP2 capsids it can form can be useful in diagnosis to detect the presence of specific CPV antibodies or to induce polyclonal or monoclonal antibodies capable of CPV detection.
  • the use of the VP2 protein hereof and of the chimeric capsids it can form for the above purposes is a further object of the present invention.
  • An additional object of this invention is a recombinant baculovirus and the process for obtaining the same, capable of producing a CPV VP2 recombinant protein identical to the viral protein, as shown in antigenic reactivity assays and other biological functionality assays.
  • the recombinant baculovirus was called AcMNPV.pCPVEx17 and filed on 2.3.91 with the European Collection of Animal Cell Cultures, (ECACC), at Porton Down, Salisbury, Wiltshire SP4 OJG (Great Britain), accession number V91030212.
  • a further object of the invention is the new baculovirus transfer vector (pCPVEx17) containing the nucleic acid sequence coding for the VP2 hereof. With a process known as AcMNPV wild strain homologous recombination this new vector leads to the said AcMNPV.pCPVEx17 recombinant baculovirus.
  • This invention also provides the nucleic acid sequence coding for the VP2 protein of the invention (FIG. 1).
  • the empty CPV chimeric capsids formed by autoassembly of the CPV recombinant VP2 proteins are yet another object of this invention.
  • SEQ. ID. NO. 1 and FIGS. 1A-E shows the nucleotide sequence coding for the VP2 hereof and the amino acid sequence thereof.
  • the nucleotide sequence is shown in direction 5'3' from left to right.
  • the amino acids have been designated using the generally accepted three-letter code.
  • FIG. 2 shows the construction of the pCPVEx17 transfer vector, pointing out the appropriate manipulations for inserting the CPV VP2 gene in the pJVP10Z plasmid.
  • FIG. 3 shows the presence of empty VP2 capsids formed by aggregation of the VP2 protein hereof, as observed under an electron microscope.
  • the invention provides a new process for obtaining a recombinant subunit vaccine serving to protect against infections due to Canine Parvovirus or related viruses such as FPLV and MEV.
  • the new vaccine can contain the CPV VP2 recombinant protein produced in an expression vector of baculoviruses multiplied in a cell culture of lepidoptera or other permissive host, or empty VP2 capsids formed by aggregating the said recombinant VP2.
  • the invention also provides a recombinant baculovirus capable of expressing the CPV VP2 when inoculated in a permissive host, and the process for obtaining the said recombinant baculovirus.
  • the obtention of the recombinant baculovirus basically comprises the following steps:
  • the recombinant baculovirus obtained thus and the proteins and capsids produced are additionally characterised.
  • the gene coding for the CPV VP2 protein is prepared in accordance with the protocol set forth in above-mentioned Spanish patent application number 9002074 and inserted in the restriction site NheI of the ACMNPV derived pJVP10Z plasmid, thereby to obtain a baculovirus transfer vector.
  • the pCPVEx17 vector proved to have the CPV DNA adequately oriented to be expressed by the AcMNPV virus polyhedrin promoter.
  • the pCPVEx17 vector was used to co-transfect permissive host cells, with the AcMNPV virus wild-type strain DNA. Reference could, inter alia, be made to cells of lepidotera or their larvae.
  • Spodoptera frugiperda (S. frugiperda) cells generally from the Sf9 strain, were transfected with pCPVEx17, though it can naturally be assumed that similar results would be achieved transfecting other permissive cells for recombinant baculovirus replication.
  • the recombinant baculoviruses were selected after removing and titrating the floats produced in confluent monolayers of S. frugiperda cells. The blue plates with no trace of the viral polyhedrin under a light microscope were collected and back-titrated on S. frugiperda cells to obtain the recombinant baculoviruses.
  • the AcMNPV.pCPVEx17 recombinant baculovirus is capable of expressing the CPV VP2 recombinant protein (VP2 hereof) and was filed with the ECACC, accession number V91030212.
  • the deposit of the recombinant baculovirus has been made on Mar. 2, 1991 with the European Collection of Animal Cell Cultures (ECACC) at the PHLS Centre of Applied Microbiology and Research, Porton Down, Salisbury, Wilts. SP4 OJG, United Kingdom.
  • a Dot Blot assay was used to verify that the VP2 gene had been adequately integrated into the said recombinant baculovirus genome.
  • the proteins expressed by the S. frugiperda cells infected with the recombinant baculovirus were analysed by electrophoresis in SDS-polyacrylamide 8% to 15% gradient gels and were stained with Coomassie blue to observe a major presence of a protein with an estimated molecular weight of 67 KDa, equivalent to that of the viral VP2 in the recombinant virus plate. Immunodetection assays showed that the anti-CPV polyclonal antisera reacted with the VP2 expressed by the recombinant baculovirus. It was also found that neutralizing monoclonal antibodies also recognized the recombinant VP2. It can in light of these results be said that the VP2 hereof expressed by the recombinant baculovirus in S. frugiperda cells is antigenically undistinguishable from the viral VP2.
  • the VP2 protein obtained with the above-described process can be used for diagnosis purposes to detect the presence of specific CPV antibodies or to induce polyclonal or monoclonal antibodies capable of CPV detection. They can further be used to immunize animals to CPV and other related viruses.
  • ELISA assays have shown that immunized animal sera recognized the viral antigens while hemagglutination inhibition assays (HI) showed that sera from animals immunized with the purified VP2 protein obtained with this invention offered HI titres equal to or greater than those obtained with other commercially available vaccines, though in some cases the response was faster and/or considerably greater when the animals were immunized with the VP2 obtained with our process (see table I).
  • the VP2 protein hereof expressed by the AcMNPC.pCPVEx17 recombinant baculovirus induces antisera capable of neutralizing CPV and protecting cell monolayers up to a dilution of 1:2000 equivalent to sera from animals that are hyperimmunized or have recovered from natural infections.
  • the VP2 protein expressed by the recombinant baculovirus vector hereof can be used to be formulated in vaccines in order to protect animals from infections caused by CPV and/or related viruses.
  • These vaccines can be both passive and active.
  • a passive vaccine could be obtained immunizing animals with the recombinant and purified VP2 hereof and then isolating polyclonal antibodies from the said VP2 which could, when purified, be used in therapeutic or prophylactic applications.
  • An active vaccine can be prepared resuspending the VP2 hereof in an immunologically acceptable diluent with an adjuvant.
  • the VP2 protein obtained with the process of this invention is peculiar in that it can be aggregated, working pursuant to our conditions, and form pseudo-viral empty VP2 capsids of regular and uniform structure and with a size of 22 nm, as shown by electron microscopy.
  • the empty capsids formed by VP2 assembly have an enhanced hemagglutination activity and are highly immunogenic, more so than other CPV recombinant proteins produced heretofore in other vectors.
  • the said capsids can hence be formulated to be used in vaccines capable of protecting animals from infections caused by CPV and/or related viruses (FPLV, MEV).
  • an active vaccine can be prepared resuspending the said capsids in an immunologically acceptable diluent, with or without an adjuvant.
  • An important feature of these empty VP2 capsids, that could be obvious to someone skilled in the art, is that they can be chemically or genetically manipulated to introduce the protein epitopes of other viruses, infection of which is to be protected, thereby to work as a polyvalent vaccine.
  • Phosphate buffer saline (PBS) solutions or other like saline solutions could be used as an immunologically acceptable diluent.
  • the adjuvant used could be alumina gel suspensions or other adjuvants regularly used in formulating vaccines.
  • a plasmidic vector AcMNPV derived with an unique cloning site NheI locus (pJVP10Z plasmid, Vialard, J. et al., J. Virol. 64, 37-50, 1990) was donated by Dr Chris Richardson (NRC. Quebec. Canada) and used to clone the XbaI fragment obtained from the pCPV12 as described in FIG. 2.
  • the said figure shows how the pCPV12 HaII fragment containing the gene coding for the CPV VP2 was cloned in pMTL24 vector AccI site flanked by two XbaI sites, leading to the pCPV13 plasmid.
  • the XbaI fragment of such plasmid was then inserted into the pJPV10Z NheI site.
  • the plasmids obtained with the VP2 gene inserted were purified in accordance with the alkalyne lysis method (Brimboim & Doly. Nucleic Acids Res. 7, 1513-1523. 1979) and characterized by restriction endonuclease mapping.
  • the pCPVEx17 recombinant proved to have adequately oriented CPV DNA for expression thereof by the AcMNPV virus polyhedrin promoter.
  • S. frugiperda cells were transfected with purified DNA mixtures from wild-type AcMNPV and pCPVEx17 plasmidic DNA in accordance with the process described by Burand et al. Virology 101. 286-290 (1980).
  • AcMNPV DNA (1 ⁇ g) purified by the method of Smith and Summers (Virology 123, 393-406. 1983) was mixed with two different quantities of plasmidic DNA (1 and 5 ⁇ g) and taken to 750 ⁇ l with Hepes buffered saline solution (25 mM Hepes, pH 7.1, 140 mM NaCl and 125 mM CaCl 2 ). The DNA solution was inoculated onto monolayers of 2 ⁇ 10 6 S.
  • frugiperda cells and incubated for 4 h at room temperature. The medium was then removed and 5 ml of medium containing 10% calf foetal serum added. After incubating for 4 days the supernatants were collected and titrated in confluent monolayers of S. frugiperda cells. To improve detection of the recombinant plaques the X-gal blue indicator was added to the agarose. Blue plates showing no traces of occlusion bodies (viral polyhedrin) under a light microscope were collected and back-titrated on S. frugiperda cells to obtain the recombinant viruses. After a third plating, high titre stocks of the recombinant viruses (10 7-8 pfu/ml) were obtained.
  • the recombinant baculovirus was called AcMNPV.pCPVEx17 and filed with the European Collection of Animal Cell Cultures (ECACC), accession number V91030212.
  • a Dot Blot assay was made to determine whether the VP2 gene had been integrated in the recombinant baculovirus genome, as follows.
  • the S. frugiperda cells were infected with the said virus at multiplicity of infection of 5 PFU/cell and incubated at 27° C. for 48 hours. The infected cells were collected, sonicated and centrifuged at 10000 rpm for 10 min to eliminate cell debris. The supernatants were used as starting material for the assays.
  • a volume of 100 ⁇ l was denatured with 10 ⁇ l of NaOH 1M, boiled for 5 min and placed immediately on ice. The mixture was neutralized with 10 ⁇ l of PO 4 H 2 Na 1M.H 2 Na 1M. A 20 ⁇ SSC solution was added immediately to obtain a final 6 ⁇ SSC concentration (SSC, citrate saline solution).
  • the solution was transferred to a nitrocellulose filter that had previously been moistened with 6 ⁇ SSC. It was washed with more 6 ⁇ SSC and dried at 37° C. for 30 min. The DNA was fixed to the nitrocellulose filter under an U.V. light for 2-3 min. The membranes were then hybridized with a specific probe of the VP2 region marked with Phosphorous-32 labeled probe at 37° C. overnight. It was then washed with decreasing SSC solutions and autoradiographed.
  • S. frugiperda cells were infected with recombinant baculovirus at a multiplicity of 5 PFU/cell and incubated at 27° C. for 48 h.
  • the cells were collected by centrifuging at 1000 rpm for 10 min, washed twice with phosphate buffered saline (PBS) solution pH 7.4 and resuspended at 1 ⁇ 10 6 cells/ml with lysis buffer (5% sodium dodecyl sulphate (SDS), 1% ⁇ -mercaptoethanol and 17.4% glycerol).
  • the samples were charged in SDS-polyacrylamide 8 to 15% gradient gels for electrophoresis and stained with Coomasie blue or transferred to nitrocellulose membranes for immunodetection.
  • the Coomasie blue tint showed the major presence of a protein with a virtual molecular weight of 67 KDa, equivalent to that of the VP2 viral protein in the recombinant virus plate.
  • the strips were then incubated for an hour at room temperature with the first anti-CPV antiserum (specific antisera or monoclonal antibodies), washed with TBS-0.05% TWEEN-20, a sorbitan derivative, namely, sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl)derivative, commercialized by Sigma Chemicals Company for 30 min at room temperature and incubated with anti-mouse rabbit serum where anti-CPV murine monoclonal antibodies was used as the first antibody at a dilution of 1:1000 for an hour at room temperature, or with anti-rabbit goat immunoglobulins marked with biotin (1:1000) where rabbit antisera was used as a first antibody.
  • TBS-0.05% TWEEN-20 a sorbitan derivative, namely, sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl)derivative
  • the strips were washed again and allowed to react with either protein A, marked with peroxidase, at a dilution of 1:1000 for an hour at room temperature, or streptavidin-peroxidase (1:2000) for 30 min at room temperature. After a thorough wash, the filters were developed with a TBS solution containing 0.5 mg/ml of 4-chloro-1-naphthol (Sigma), 17% (v/v) of methanol and 0.015% of hydrogen peroxide in TBS until visible bands appeared. The reaction was stopped treating the strips with distilled water.
  • S. frugiperda cells were infected with AcMNPV.pCPVEx17 recombinant virus at a multiplicity of infection of 5-10 PFU/cell and incubated at 27° C. for 48-72 h.
  • the cells were collected by centrifuging at 1000 rpm for 10 min, washed twice in a phosphate buffered saline solution pH 7.4 and resuspended at 2 ⁇ 10 7 cells/ml in a 25 mM pH 9.5 bicarbonate buffer.
  • the resuspended cells were broken down by sonication and centrifuged at 10,000 rpm for 10 min to eliminate cell remains.
  • the supernatant containing the recombinant VP2 protein can be purified using its autoaggregating capacity to form empty capsids. They are to this end either purified by 20% ammonium sulphate precipitation or the empty capsids are centrifuged on CsCl gradients at 45,000 rpm for 14 h. Capsids offer a buoyant density ( ⁇ ) of 1.30 g/cm 3 when banded in CsCl gradient. Preparation purity was determined by electrophoresis in SDS-polyacrylamide gels as per the method described above and VP2 protein purity turned out to be in excess of 99%.
  • Recombinant protein functionality was analysed by a hemagglutination assay (HA). This activity is only associated to the particulate character of the product, thereby clearly distinguishing the same from previous ones.
  • 50 ⁇ l are mixed in a solution containing several factor two dilutions of a viral preparation with 50 ⁇ l of a solution containing 1% pig erythrocytes in phosphate buffer pH 6.5 and left at 4° C. for at least 4 h in round bottom plates.
  • a purified VP2 preparation was stained by negative contrast with 2% uranyl acetate and observed under an electron microscope at a magnifying power of 40,000 ⁇ 2.5, the presence of a large number of pseudo-viral chimeric particles of regular and uniform structure and with a size of roughly 22 nm being observed. (FIG. 3).
  • Two New Zealand rabbits weighing 2 kg were intramuscularly immunized three times (days 0, 15 and 30) with 100 ⁇ g of a purified VP2 preparation. The first time in complete Freund adjuvant, the second and third times with Freund's incomplete adjuvant. A week after the last immunization the rabbit was bled and the serum obtained tested with an ELISA assay, an hemagglutination inhibition assay (IHA) and an in vitro CPV neutralization assay, as described hereinbelow.
  • IHA hemagglutination inhibition assay
  • HI and neutralization assays were used to assess the capacity of these preparations to induce CPV protection in dogs.
  • Pollock and Carmichael (Cornell Vet. 72, 16-35, 1982) had previously shown that there is a good correlation between HI titre and protection; dogs showing HI>80 titres are considered refractory to CPV infection.
  • All dogs vaccinated with our preparation showed high HI titres, between 150 and 5,120 (Table I). Sufficient HI titres lasted for over 2 months. A good correlation was found between HI titres and monolayer protection neutralisation.
  • the titres obtained are in both cases far higher, even at lower doses (10 ⁇ g/dog) than what is needed to obtain a protective response in dogs.
  • the titres were similar to those achieved with sera of dogs who had recovered from parvovirosis infection and much higher than those obtained with the vaccinated control. No anti-CPV antibodies were detected in the serum of dogs that were not inoculated.
  • the presence of specific CPV antibodies in the serum of immunized animals was determined by means of an indirect ELISA assay.
  • the antigen used was both purified virus and purified VP2 protein. Briefly, polystyrene plates were coated with 0.5 ⁇ g of virus or 0.25 ⁇ g/well of VP2 in 100 ⁇ l of carbonate buffer (0.05M, pH 9.6) at 4° C. overnight.
  • the plates were washed with PBS (0.15M NaCl in 0.1M sodium phosphate, pH 7.4) containing 0.05% TWEEN-20TM and incubated with the antiserum for 2 h at 37° C., washed again and incubated with either anti-rabbit goat IgG marked with biotin, where rabbit sera was used, or with protein A labeled with peroxidase if dog sera were used, for 1 h at room temperature. The antibody marked with biotin was later incubated with streptavidin marked with peroxidase for 30 min at room temperature.
  • the ELISA titre obtained was 1/6400 for the complete virus.
  • the antisera recognised the viral antigen in an ELISA assay perfectly, with complete virus titres of up to 1/5120 for the 100 ⁇ g dose.
  • the sera were inactivated at 56° C. for 30 min and adsorbed with 0.25% Kaolin for 1 h at room temperature whereupon the immunized dog sera was diluted (factor two) in a phosphate buffer pH 6.5, starting with a 1:20 dilution. 25 ⁇ l of each of the previous dilutions were mixed with 25 ⁇ l of a virus dilution containing 4 units of HA, and incubated for 2 h at 37° C. 50 ⁇ l of 1% pig erythrocytes were then added in a phosphate buffer pH 6.5 and left at 4° C. for at least 4 h in round bottom plates.
  • Neutralization was determined by means of a monolayer protection test. Briefly, a known quantity of CPV (100 units of HA) was incubated with rabbit antiserum at different dilutions for 2 hours at 37° C. The samples were then inoculated on CRFK susceptible cell monolayers for 90 min at 37° C. The monolayers were covered with 1 ml of agarose at 1% in a fresh medium. Five days after infection the cells were fixed with 10% formaldehyde in PBS for 20 min, the agarose was removed and the remaining cells stained with 1% violet crystal in 50% ethanol for 20 min. The level of protection was assessed by screening the infected monolayers.
  • the rabbit antiserum induced by the pCPVEx17 plasmid protein is able to protect the cellular monolayer from the infection up to a dilution of 1:2000, equivalent to sera from animals that are hyperimmunized or have recovered from natural infections.
  • the feline panleukopenia virus cats
  • the mink enteritis virus minks
  • the same VP2 particles may be used to render cats and minks immune to parvovirus, as is the case with conventional vaccines.
  • the dogs used in the challenge test were immunized as follows: 1. Sentinel dog. 2. Dog vaccinated with an inactivated commercial vaccine. 3. Dog vaccinated with 50 ⁇ g of VP2 adjuvanted with Quil-A (quillaic acid). 4. Dog vaccinated with 50 ⁇ g of VP2 adjuvanted with alumina and Quil-A(quillaic acid). 5. Dog vaccinated with 25 ⁇ g of VP2 adjuvanted with alumina and Quil-A(quillaic acid). 6. Dog vaccinated with 10 ⁇ g of VP2 adjuvanted with alumina and Quil-A(quillaic acid).
  • a passive vaccine can be obtained immunizing animals with the purified recombinant VP2 vaccines as described herein.
  • Polyclonal antibodies directed against this VP2 can be isolated from serum, milk or other animal bodily fluids. These antibodies can then be purified and used for therapeutic or prophylactic applications.
  • An active vaccine can be prepared resuspending the recombinant VP2 capsids described herein in an immunologically acceptable diluent such as PBS and an adjuvant such as ALHYDROGELTM or QuillATM.
  • an adjuvant such as ALHYDROGELTM or QuillATM.
  • Initial and second injections or oral administration of the vaccinal solution can be used to confer immunity.
  • An active vaccine can also be prepared resuspending the empty capsids in an immunologically acceptable diluent with or without an adjuvant.
  • the AcMNPV.pCPVEx17 baculovirus is capable of producing a recombinant VP2 absolutely identical to the viral VP2 protein, as shown with the DNA sequence, molecular weight estimate and antigenic characterization.
  • the VP2 obtained herein with our process is also remarkably capable of forming empty capsids, thereby providing the same with a hemagglutination and immunogenic activity that is clearly greater than in other previously described recombinant proteins, as shown with the animal immunisation tests herein described.
  • This enhanced immunogenic capacity can be used by those skilled in the art to present other viral protein epitopes, that can be introduced therein by either chemical or genetic manipulation of the recombinant baculoviruses.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
US08/317,785 1991-03-26 1994-10-04 Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids Expired - Fee Related US5882652A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/317,785 US5882652A (en) 1991-03-26 1994-10-04 Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES9100844 1991-03-26
ES9100844A ES2026826A6 (es) 1991-03-26 1991-03-26 Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
PCT/ES1992/000031 WO1992017205A1 (fr) 1991-03-26 1992-03-26 Procede de production d'un vaccin sous-unitaire contre le parvovirus canin et autres virus apparentes
US98357793A 1993-01-26 1993-01-26
US08/317,785 US5882652A (en) 1991-03-26 1994-10-04 Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US98357793A Continuation 1991-03-26 1993-01-26

Publications (1)

Publication Number Publication Date
US5882652A true US5882652A (en) 1999-03-16

Family

ID=8271929

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/317,785 Expired - Fee Related US5882652A (en) 1991-03-26 1994-10-04 Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids

Country Status (8)

Country Link
US (1) US5882652A (fr)
EP (1) EP0554414B1 (fr)
AT (1) ATE161729T1 (fr)
AU (1) AU1585092A (fr)
DE (1) DE69223939T2 (fr)
DK (1) DK0554414T3 (fr)
ES (1) ES2026826A6 (fr)
WO (1) WO1992017205A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187759B1 (en) * 1997-02-12 2001-02-13 Akzo Nobel N.V. Canine parvovirus DNA vaccination
US6465438B1 (en) * 1996-04-19 2002-10-15 Metin Colpan Nucleic acid vaccination for parvoviral infections
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
US20060204479A1 (en) * 1998-11-05 2006-09-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US20080269149A1 (en) * 2004-12-15 2008-10-30 Bowles Dawn E Chimeric Vectors
US20090010955A1 (en) * 2007-06-14 2009-01-08 The Board Of Regents For Oklahoma State University Vaccines Containing Canine Parvovirus Genetic Variants
US20090098152A1 (en) * 2007-06-14 2009-04-16 The Board Of Regents For Oklahoma State University Vaccines Containing Canine Parvovirus Genetic Variants
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
WO2010088552A1 (fr) 2009-01-30 2010-08-05 The Board Of Regents For Oklahoma State University Compositions immunogènes, vaccins et diagnostics à base de virus de la maladie de carré circulant chez les chiens nord-américains
WO2010093784A2 (fr) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
WO2011047158A1 (fr) 2009-10-14 2011-04-21 The Board Of Regents For Oklahoma State University Isolement d'un virus apparenté au parvovirus canin de type 2 à partir d'un raton laveur
WO2011088081A1 (fr) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Répétitions terminales inversées restrictives pour vecteurs viraux
WO2012109570A1 (fr) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
WO2014052789A1 (fr) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
WO2014143932A1 (fr) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
WO2014144229A1 (fr) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Méthodes et compositions de double liaison de glycane de vecteurs avv
WO2016115382A1 (fr) 2015-01-14 2016-07-21 The University Of North Carolina At Chapel Hill Procédés et compositions destinés au transfert de gènes ciblé
WO2016127057A1 (fr) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Cassettes optimisées d'expression génétique du facteur viii de coagulation humain et leur utilisation
WO2017058892A2 (fr) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Procédés et compositions pour vecteurs viraux évitant les anticorps
WO2017106236A1 (fr) 2015-12-14 2017-06-22 The University Of North Carolina At Chapel Hill Protéines capsidiques modifiées pour la libération améliorée de vecteurs parvoviraux
WO2018170310A1 (fr) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Vecteurs viraux adéno-associés polyploïdes et leurs procédés de fabrication et d'utilisation
WO2019195423A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus permettant de cibler des tissus ophtalmiques
WO2019195449A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus évitant les anticorps
WO2019195444A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs viraux évitant les anticorps
WO2019241324A1 (fr) 2018-06-12 2019-12-19 The University Of North Carolina At Chapel Hill Capsides synthétiques de virus adéno-associé du foie et leurs utilisations
US10585103B2 (en) 2016-04-28 2020-03-10 The Trustees Of Indiana University Methods and compositions for resolving components of a virus preparation
WO2020191300A1 (fr) 2019-03-21 2020-09-24 Stridebio, Inc. Vecteurs viraux adéno-associés recombinants
CN112553168A (zh) * 2020-12-23 2021-03-26 江苏省农业科学院 分泌抗猫细小病毒vp2蛋白单克隆抗体的杂交瘤细胞3a6株及其应用
WO2021076925A1 (fr) 2019-10-17 2021-04-22 Stridebio, Inc. Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c
US11177122B2 (en) 2018-06-04 2021-11-16 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
US11227758B2 (en) 2018-06-04 2022-01-18 The Trustees Of Indiana University Apparatus and method for capturing ions in an electrostatic linear ion trap
US11227759B2 (en) 2018-06-04 2022-01-18 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
US11257665B2 (en) 2018-06-04 2022-02-22 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
US11315780B2 (en) 2018-06-04 2022-04-26 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
WO2022093769A1 (fr) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
WO2022155482A1 (fr) 2021-01-14 2022-07-21 Stridebio, Inc. Vecteurs de vaa ciblant des lymphocytes t
WO2022221529A1 (fr) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Virions de vaa à polyploïde rationnel traversant la barrière hémato-encéphalique et déclenchant une réponse humorale réduite
US11495449B2 (en) 2018-11-20 2022-11-08 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
US11562896B2 (en) 2018-12-03 2023-01-24 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
EP4169535A1 (fr) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
US11639509B2 (en) 2020-10-28 2023-05-02 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
US11668719B2 (en) 2017-09-20 2023-06-06 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
WO2023150687A1 (fr) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Vecteurs viraux adéno-associés recombinants et méthodes d'utilisation associées
US11942317B2 (en) 2019-04-23 2024-03-26 The Trustees Of Indiana University Identification of sample subspecies based on particle mass and charge over a range of sample temperatures
EP4344741A2 (fr) 2014-11-21 2024-04-03 The University of North Carolina at Chapel Hill Vecteurs aav ciblant le système nerveux central
WO2024124019A2 (fr) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Vecteurs aav ciblant des cellules souches hématopoïétiques
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
US12112936B2 (en) 2019-09-25 2024-10-08 The Trustees Of Indiana University Apparatus and method for pulsed mode charge detection mass spectrometry

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001833A1 (fr) * 1991-07-17 1993-02-04 Commonwealth Scientific And Industrial Research Organisation Vaccin ameliore
DE69415462T2 (de) * 1993-01-23 1999-07-15 Inmunologia Y Genetica Aplicada, S.A., Madrid Synthetischen peptiden und impfstoffe gegen parvovirus
ES2065254B1 (es) * 1993-01-23 1995-07-16 Inmunologia & Genetica Aplic Peptidos y vacunas sinteticas contra parvovirus canino y otros virus relacionados.
US5885585A (en) * 1994-11-08 1999-03-23 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
US5814510A (en) * 1994-11-08 1998-09-29 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
EP0959893A4 (fr) 1996-12-10 2004-11-10 Sloan Kettering Institutefor C Procede et compositions destines a stimuler une reponse immune a l'egard d'un antigene de differenciation stimule par un antigene modifie
US7556805B2 (en) 1996-12-10 2009-07-07 Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center Compositions for treatment of melanoma and method of using same
EP0863151A1 (fr) * 1997-02-12 1998-09-09 Akzo Nobel N.V. Vaccins en ADN contre le parvovirus canin
US8021666B2 (en) 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
CZ287956B6 (cs) * 1997-11-04 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě parvovirózy psů
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
CA2373110A1 (fr) * 2000-03-14 2001-09-20 Neurologix, Inc. Production de vecteurs de capsides chimeres
CN104388394B (zh) * 2014-10-22 2017-03-15 中国农业科学院特产研究所 水貂细小病毒弱毒疫苗株及其在制备水貂细小病毒弱毒疫苗中的用途
CN107827958B (zh) * 2017-11-11 2020-08-25 中牧实业股份有限公司 犬细小病毒合成肽疫苗及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002026A1 (fr) * 1986-09-08 1988-03-24 Applied Biotechnology, Inc. Vaccins de capsides viraux vides
US4857634A (en) * 1985-04-03 1989-08-15 National Research Development Corporation Peptides useful in vaccination against enteroviruses
US4870023A (en) * 1987-03-16 1989-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
EP0341611A2 (fr) * 1988-05-09 1989-11-15 Boyce Thompson Institute For Plant Research, Inc. Vaccin à base de sous-unité du parvovirus canin et sa méthode de production
US5508186A (en) * 1988-11-14 1996-04-16 The United States Of America As Represented By The Secretary Of Health And Human Services B19 parvovirus capsids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193990A (en) * 1979-02-16 1980-03-18 Cornell Research Foundation, Inc. Heterotypic canine parvovirus vaccine
DE69415462T2 (de) * 1993-01-23 1999-07-15 Inmunologia Y Genetica Aplicada, S.A., Madrid Synthetischen peptiden und impfstoffe gegen parvovirus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857634A (en) * 1985-04-03 1989-08-15 National Research Development Corporation Peptides useful in vaccination against enteroviruses
WO1988002026A1 (fr) * 1986-09-08 1988-03-24 Applied Biotechnology, Inc. Vaccins de capsides viraux vides
US4870023A (en) * 1987-03-16 1989-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
EP0341611A2 (fr) * 1988-05-09 1989-11-15 Boyce Thompson Institute For Plant Research, Inc. Vaccin à base de sous-unité du parvovirus canin et sa méthode de production
US4971793A (en) * 1988-05-09 1990-11-20 Boyce Thompson Institute For Plant Research, Inc. Subunit canine parvovirus vaccine
US5508186A (en) * 1988-11-14 1996-04-16 The United States Of America As Represented By The Secretary Of Health And Human Services B19 parvovirus capsids

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Antibodies, A Laboratory Manual Ed. E.Harlow and D. Lane Cold Spring Harbor Laboratory 1988 see pp. 298, 446 & 447. *
Harlow and Lane (Ed.) "Antibodies, A Laboratory Manual", published in 1988 by Cold Spring Harbor Laboratory, see pp. 98, 99, 298, 299, 446, 447, and 450.
Harlow and Lane (Ed.) Antibodies, A Laboratory Manual , published in 1988 by Cold Spring Harbor Laboratory, see pp. 98, 99, 298, 299, 446, 447, and 450. *
Kajigaya et al. PNAS (88):4646 4650 Jun. 1991. *
Kajigaya et al. PNAS (88):4646-4650 Jun. 1991.
Lopez et al. J. Virol 66(5):2748 53, May 1992. *
Lopez et al. J. Virol 66(5):2748-53, May 1992.
Reed et al. J. Virol 62(1):226 76, 1988. *
Reed et al. J. Virol 62(1):226-76, 1988.
Tretschin et al. J.Gen.Virol. 61:33 41, 1982. *
Tretschin et al. J.Gen.Virol. 61:33-41, 1982.
Vialerd et al. J. Virol. 64(1):37 50 Jan. 1990. *
Vialerd et al. J. Virol. 64(1):37-50 Jan. 1990.

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465438B1 (en) * 1996-04-19 2002-10-15 Metin Colpan Nucleic acid vaccination for parvoviral infections
US6187759B1 (en) * 1997-02-12 2001-02-13 Akzo Nobel N.V. Canine parvovirus DNA vaccination
US9567607B2 (en) 1998-11-05 2017-02-14 Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US8637255B2 (en) 1998-11-05 2014-01-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US20060204479A1 (en) * 1998-11-05 2006-09-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US20080008684A1 (en) * 1998-11-05 2008-01-10 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US20080050345A1 (en) * 1998-11-05 2008-02-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US20080050343A1 (en) * 1998-11-05 2008-02-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cell containing same
US9163260B2 (en) 1998-11-05 2015-10-20 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
US20060188484A1 (en) * 1998-11-10 2006-08-24 Rabinowitz Joseph E Virus vectors and methods of making and administering the same
US20060188483A1 (en) * 1998-11-10 2006-08-24 Rabinowitz Joseph E Virus vectors and methods of making and administering the same
US7172893B2 (en) 1998-11-10 2007-02-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US20030053990A1 (en) * 1998-11-10 2003-03-20 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
US20080269149A1 (en) * 2004-12-15 2008-10-30 Bowles Dawn E Chimeric Vectors
US9012224B2 (en) 2004-12-15 2015-04-21 The University Of North Carolina At Chapel Hill Chimeric vectors
US20110104119A1 (en) * 2004-12-15 2011-05-05 Bowles Dawn E Chimeric Vectors
US7892809B2 (en) 2004-12-15 2011-02-22 The University Of North Carolina At Chapel Hill Chimeric vectors
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
US8258274B2 (en) 2007-06-14 2012-09-04 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
US8227583B2 (en) * 2007-06-14 2012-07-24 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
US8609404B2 (en) 2007-06-14 2013-12-17 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
US20090010955A1 (en) * 2007-06-14 2009-01-08 The Board Of Regents For Oklahoma State University Vaccines Containing Canine Parvovirus Genetic Variants
US20090098152A1 (en) * 2007-06-14 2009-04-16 The Board Of Regents For Oklahoma State University Vaccines Containing Canine Parvovirus Genetic Variants
WO2010088552A1 (fr) 2009-01-30 2010-08-05 The Board Of Regents For Oklahoma State University Compositions immunogènes, vaccins et diagnostics à base de virus de la maladie de carré circulant chez les chiens nord-américains
US20100196420A1 (en) * 2009-01-30 2010-08-05 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
US8647637B2 (en) 2009-01-30 2014-02-11 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
WO2010093784A2 (fr) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
US9475845B2 (en) 2009-02-11 2016-10-25 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2011047158A1 (fr) 2009-10-14 2011-04-21 The Board Of Regents For Oklahoma State University Isolement d'un virus apparenté au parvovirus canin de type 2 à partir d'un raton laveur
WO2011088081A1 (fr) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Répétitions terminales inversées restrictives pour vecteurs viraux
EP4234571A2 (fr) 2011-02-10 2023-08-30 The University of North Carolina at Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
WO2012109570A1 (fr) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
WO2014052789A1 (fr) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
EP3738974A1 (fr) 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
EP3517612A1 (fr) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
WO2014143932A1 (fr) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
US12049478B2 (en) 2013-03-15 2024-07-30 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
US10077291B2 (en) 2013-03-15 2018-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
WO2014144229A1 (fr) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Méthodes et compositions de double liaison de glycane de vecteurs avv
US11059862B2 (en) 2013-03-15 2021-07-13 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
EP3838297A1 (fr) 2013-03-15 2021-06-23 The University of North Carolina at Chapel Hill Méthodes et compositions de double liaison de glycane de vecteurs avv
EP4344741A2 (fr) 2014-11-21 2024-04-03 The University of North Carolina at Chapel Hill Vecteurs aav ciblant le système nerveux central
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
WO2016115382A1 (fr) 2015-01-14 2016-07-21 The University Of North Carolina At Chapel Hill Procédés et compositions destinés au transfert de gènes ciblé
WO2016127057A1 (fr) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Cassettes optimisées d'expression génétique du facteur viii de coagulation humain et leur utilisation
EP3611186A1 (fr) 2015-02-06 2020-02-19 The University of North Carolina at Chapel Hill Cassettes optimisées d'expression génétique du facteur viii de coagulation humain et leur utilisation
US10745447B2 (en) 2015-09-28 2020-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11840555B2 (en) 2015-09-28 2023-12-12 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017058892A2 (fr) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Procédés et compositions pour vecteurs viraux évitant les anticorps
EP3831842A1 (fr) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Procédés et compositions pour vecteurs viraux évitant les anticorps
US11208438B2 (en) 2015-09-28 2021-12-28 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017106236A1 (fr) 2015-12-14 2017-06-22 The University Of North Carolina At Chapel Hill Protéines capsidiques modifiées pour la libération améliorée de vecteurs parvoviraux
US10585103B2 (en) 2016-04-28 2020-03-10 The Trustees Of Indiana University Methods and compositions for resolving components of a virus preparation
EP4303225A2 (fr) 2017-03-15 2024-01-10 The University of North Carolina at Chapel Hill Vecteurs viraux adéno-associés polyploïdes et leurs procédés de fabrication et d'utilisation
WO2018170310A1 (fr) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Vecteurs viraux adéno-associés polyploïdes et leurs procédés de fabrication et d'utilisation
US11668719B2 (en) 2017-09-20 2023-06-06 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
US11867700B2 (en) 2017-09-20 2024-01-09 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
US11646191B2 (en) 2018-01-12 2023-05-09 The Trustees Of Indiana University Instrument, including an electrostatic linear ion trap, for separating ions
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
US12060390B2 (en) 2018-04-03 2024-08-13 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US11976096B2 (en) 2018-04-03 2024-05-07 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
WO2019195423A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus permettant de cibler des tissus ophtalmiques
WO2019195449A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs de virus évitant les anticorps
WO2019195444A1 (fr) 2018-04-03 2019-10-10 Stridebio, Inc. Vecteurs viraux évitant les anticorps
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12116384B2 (en) 2018-04-03 2024-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
US11862448B2 (en) 2018-06-04 2024-01-02 The Trustees Of Indiana University Instrument, including an electrostatic linear ion trap with charge detector reset or calibration, for separating ions
US11227758B2 (en) 2018-06-04 2022-01-18 The Trustees Of Indiana University Apparatus and method for capturing ions in an electrostatic linear ion trap
US11532471B2 (en) 2018-06-04 2022-12-20 The Trustees Of Indiana University Instrument for separating ions including an interface for transporting generated ions thereto
US11177122B2 (en) 2018-06-04 2021-11-16 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
US11594405B2 (en) 2018-06-04 2023-02-28 The Trustees Of Indiana University Charge detection mass spectrometer including gain drift compensation
US11227759B2 (en) 2018-06-04 2022-01-18 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
US11257665B2 (en) 2018-06-04 2022-02-22 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
US11315780B2 (en) 2018-06-04 2022-04-26 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
US11682545B2 (en) 2018-06-04 2023-06-20 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
WO2019241324A1 (fr) 2018-06-12 2019-12-19 The University Of North Carolina At Chapel Hill Capsides synthétiques de virus adéno-associé du foie et leurs utilisations
US11682546B2 (en) 2018-11-20 2023-06-20 The Trustees Of Indiana University System for separating ions including an orbitrap for measuring ion mass and charge
US11495449B2 (en) 2018-11-20 2022-11-08 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
US11562896B2 (en) 2018-12-03 2023-01-24 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
WO2020191300A1 (fr) 2019-03-21 2020-09-24 Stridebio, Inc. Vecteurs viraux adéno-associés recombinants
US11942317B2 (en) 2019-04-23 2024-03-26 The Trustees Of Indiana University Identification of sample subspecies based on particle mass and charge over a range of sample temperatures
EP4169535A1 (fr) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
US12112936B2 (en) 2019-09-25 2024-10-08 The Trustees Of Indiana University Apparatus and method for pulsed mode charge detection mass spectrometry
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
WO2021076925A1 (fr) 2019-10-17 2021-04-22 Stridebio, Inc. Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
US11639509B2 (en) 2020-10-28 2023-05-02 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
WO2022093769A1 (fr) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
CN112553168B (zh) * 2020-12-23 2022-03-08 江苏省农业科学院 分泌抗猫细小病毒vp2蛋白单克隆抗体的杂交瘤细胞3a6株及其应用
CN112553168A (zh) * 2020-12-23 2021-03-26 江苏省农业科学院 分泌抗猫细小病毒vp2蛋白单克隆抗体的杂交瘤细胞3a6株及其应用
WO2022155482A1 (fr) 2021-01-14 2022-07-21 Stridebio, Inc. Vecteurs de vaa ciblant des lymphocytes t
WO2022221529A1 (fr) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Virions de vaa à polyploïde rationnel traversant la barrière hémato-encéphalique et déclenchant une réponse humorale réduite
WO2023150687A1 (fr) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Vecteurs viraux adéno-associés recombinants et méthodes d'utilisation associées
WO2024124019A2 (fr) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Vecteurs aav ciblant des cellules souches hématopoïétiques

Also Published As

Publication number Publication date
DE69223939T2 (de) 1998-07-09
WO1992017205A1 (fr) 1992-10-15
ATE161729T1 (de) 1998-01-15
EP0554414B1 (fr) 1998-01-07
DK0554414T3 (da) 1998-09-07
DE69223939D1 (de) 1998-02-12
EP0554414A1 (fr) 1993-08-11
ES2026826A6 (es) 1992-05-01
AU1585092A (en) 1992-11-02

Similar Documents

Publication Publication Date Title
US5882652A (en) Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids
US5498413A (en) Recombinant subunit vaccine against porcine parvovirus
Martínez et al. Production of porcine parvovirus empty capsids with high immunogenic activity
Roy et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection
EP0273366B1 (fr) La synthèse et le pouvoir immunogène de gènes du rotavirus utilisant un système d'expression de baculovirus
KR100204438B1 (ko) 치킨 아네미아 바이러스 백신 및 진단방법
Anderson et al. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicitneutralizing antibodies in rabbits
Langeveld et al. Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein
US4971793A (en) Subunit canine parvovirus vaccine
Casal Use of parvovirus‐like particles for vaccination and induction of multiple immune responses
Shivappa et al. Using a baculovirus insect/larvae
EP0491824B1 (fr) Proteines du parvovirus b19 humain et particules d'aspect viral, leur production et leur utilisation dans les analyses diagnostiques et les vaccins
AU680264B2 (en) Synthetic peptides and vaccines against parvovirus
JPH05292976A (ja) マレック病ウイルスワクチン
WO1984002847A1 (fr) Procedes et materiaux de developpement des vaccins du parvovirus
EP0704528B1 (fr) Virus de l'hémorragie des lapins (RHDV), capsides recombinants, protéines, et trousse de diagnostic et vaccins les contenant
US6379885B1 (en) Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
US6204044B1 (en) Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
US6241989B1 (en) Recombinant multivalent viral vaccine
US7087234B1 (en) Recombinant multivalent viral vaccine
AU667796B2 (en) Production of antigens by self-assembly of polypeptide components
Khodabandehloo et al. Cloning and expression of simian rotavirus spike protein (VP4) in insect cells by baculovirus expression system
US5686270A (en) Production of antigens by self-assembly of polypeptide components
MXPA97009851A (en) Epithopes conformational neutralizers of poem anemia viruses

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110316